Climb Bio, Inc. (CLYM)

Climb Bio, Inc. is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. The company, formerly known as Eliem Therapeutics, is headquartered in Wellesley Hills, Massachusetts.

Its lead candidate, budoprutug, is an antibody that targets CD19, a protein found on B cells, and is being studied in diseases driven by B cells, including primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus. Climb Bio is also developing CLYM116, a preclinical antibody that targets APRIL, a signaling protein involved in B-cell and antibody activity, for IgA nephropathy and related conditions. Its common stock trades on Nasdaq under the ticker CLYM.